Sylvia A. Holden

Differentiation and reversal of malignant changes in colon cancer through PPARγ

Pasha Sarraf, Elisabetta Mueller, Daniel M. Jones et al. · Nature Medicine · 1998 · 969 citations

Tumor Biology, Malignant Changes, Gastrointestinal Oncology +9

Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo.

Tetsuya Kubota, Kozo Koshizuka, Elizabeth A. Williamson et al. · PubMed · 1998 · 588 citations

Tumor Biology, Urology, Medicine +13

Tumor Resistance to Alkylating Agents Conferred by Mechanisms Operative Only in Vivo

Beverly A. Teicher, Terence S. Herman, Sylvia A. Holden et al. · Science · 1990 · 316 citations

Vivo Passage, Medicine, Pharmacology +13

Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II).

Beverly A. Teicher, Sylvia A. Holden, Michael J. Kelley et al. · PubMed · 1987 · 291 citations

Chemoprevention Strategy, Pathology, Metronomic Chemotherapy +17

Potentiation of cytotoxic cancer therapies by TNP‐470 alone and with other anti‐angiogenic agents

Beverly A. Teicher, Sylvia A. Holden, Gulshan Ara et al. · International Journal of Cancer · 1994 · 233 citations